ERBB2 and neoplasm: Early clinical trials employing first-generation CAR-T cells targeting antigens such as HER2 and CAIX in glioblastoma and renal cell carcinoma, respectively, revealed limited therapeutic benefit, primarily due to poor in vivo persistence and off-tumour toxicities [27–29].